KaydedilenlerDerginizi ekleyin

Dergiler / Southern Clinics of Istanbul Eurasia / 2021 / Cilt: 32 - Sayı: 3

Five-Year Outcomes of Subthreshold Yellow Micropulse Laser Treatment in Chronic Central Serous Chorioretinopathy: Could it be Any Marker of Response to Treatment?

Aysu ARSAN
Aysegul PENBE
Hatice Selen Sönmez KANAR
Ayse SONMEZ
Yelda OZKURT
Sayfa
304–310
Yayın Tarihi
2022-10-19
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Results: The mean BCVA improved from 0.46±0.25 Log MAR to 0.11±0.22 Log MAR and the mean CMT decreased from 404.60±72.46 µm to 243.50±24.97 µm at last visit (p

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: The aim of the study was to assess the results of 577 nm subthreshold yellow micropulse laser treatment (SYMLT) in patients with chronic central serous chorioretinopathy (CSC) with a five-year follow-up.
📊
Temel Bulgular & Veri:Methods: A total of 81 eyes of 72 patients with chronic CSC were followed for at least 5 years.
💡
Sonuç & Katkı:Results: The mean BCVA improved from 0.46±0.25 Log MAR to 0.11±0.22 Log MAR and the mean CMT decreased from 404.60±72.46 µm to 243.50±24.97 µm at last visit (p
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: The aim of the study was to assess the results of 577 nm subthreshold yellow micropulse laser treatment (SYMLT) in patients with chronic central serous chorioretinopathy (CSC) with a five-year follow-up. We also evaluated the effect of baseline characteristics on relapse and the SYMLT treatment responses. Methods: A total of 81 eyes of 72 patients with chronic CSC were followed for at least 5 years. Patients were treated with 577-nm SMYLT in multiple sessions at a 5% duty cycle. Best-corrected visual acuity (BCVA), central macular thickness (CMT), central macular volume (CMV), total macular volume (TMV) and subfoveal choroidal thickness (SFCT) were measured by spectral-domain optical coherence tomography (SD-OCT). Other basic SDOCT parameters were recorded. Results: The mean BCVA improved from 0.46±0.25 Log MAR to 0.11±0.22 Log MAR and the mean CMT decreased from 404.60±72.46 µm to 243.50±24.97 µm at last visit (p

🔖

Bu Makaleye Atıf Yap

ARSAN, A., PENBE, A., KANAR, H. S. S., SONMEZ, A., OZKURT, Y. (2022). Five-Year Outcomes of Subthreshold Yellow Micropulse Laser Treatment in Chronic Central Serous Chorioretinopathy: Could it be Any Marker of Response to Treatment?. Southern Clinics of Istanbul Eurasia, Cilt: 32 - Sayı: 3, 304–310. https://ajindex.com/articles/592754

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Haimovici R, Koh S, Gagnon DR, Lehrfeld T, Wellik S; Central Serous Chorioretinopathy Case-Control Study Group. Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology 2004;111:244–9
  2. Loo RH, Scott IU, Flynn HW Jr, Gass JD, Murray TG, Lewis ML, et al. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina 2002;22:19–24
  3. Bujarborua D. Long-term follow-up of idiopathic central serous chorioretinopathy without laser. Acta Ophthalmol Scand 2001;79:417– 21
  4. Sartini F, Figus M, Nardi M, Casini G, Posarelli C. Non-resolving, recurrent and chronic central serous chorioretinopathy: available treatment options. Eye (Lond) 2019;33:1035–43
  5. Wong KH, Lau KP, Chhablani J, Tao Y, Li Q, Wong IY. Central serous chorioretinopathy: what we have learnt so far. Acta Ophthalmol 2016;94:321–5
  6. Hanumunthadu D, Tan ACS, Singh SR, Sahu NK, Chhablani J. Management of chronic central serous chorioretinopathy. Indian J Ophthalmol 2018;66:1704–14
  7. Nicolò M, Desideri LF, Vagge A, Traverso CE. Current pharmacological treatment options for central serous chorioretinopathy: a review. Pharmaceuticals (Basel) 2020;13:264
  8. Ober MD, Yannuzzi LA, Do DV, Spaide RF, Bressler NM, Jampol LM, et al. Photodynamic therapy for focal retinal pigment epithelial leaks secondary to central serous chorioretinopathy. Ophthalmology 2005;112:2088–94
  9. Yannuzzi LA, Slakter JS, Gross NE, Spaide RF, Costa DL, Huang SJ, et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. 2003. Retina 2012;32 Suppl 1:288–98
  10. Dorin G. Evolution of retinal laser therapy: minimum intensity photocoagulation (MIP). Can the laser heal the retina without harming it? Semin Ophthalmol 2004;19:62–8
  11. Sramek C, Mackanos M, Spitler R, Leung LS, Nomoto H, Contag CH, et al. Non-damaging retinal phototherapy: dynamic range of heat shock protein expression. Invest Ophthalmol Vis Sci 2011;52:1780– 7
  12. Malik KJ, Sampat KM, Mansouri A, Steiner JN, Glaser BM. Low-intensity/high-density subthreshold microPulse diode laser for chronic central serous chorioretinopathy. Retina 2015;35:532–6
  13. Gawęcki M, Jaszczuk-Maciejewska A, Jurska-Jaśko A, Grzybowski A. Functional and morphological outcome in patients with chronic central serous chorioretinopathy treated by subthreshold micropulse laser. Graefes Arch Clin Exp Oph